Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued on Thursday.
Lexicon Pharmaceuticals Stock Performance
Shares of Lexicon Pharmaceuticals stock opened at $2.08 on Thursday. The business's fifty day simple moving average is $2.14 and its 200 day simple moving average is $2.37. The firm has a market capitalization of $392.55 million, a P/E ratio of -3.35 and a beta of 1.34. Lexicon Pharmaceuticals has a 12 month low of $1.31 and a 12 month high of $4.72. The company has a current ratio of 7.54, a quick ratio of 7.54 and a debt-to-equity ratio of 0.17.
Get
Lexicon Pharmaceuticals alerts:
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. The business had revenue of $0.04 million for the quarter. Lexicon Pharmaceuticals had a negative return on equity of 92.19% and a negative net margin of 77,648.80%. As a group, analysts anticipate that Lexicon Pharmaceuticals will post -0.6 EPS for the current year.
Institutional Trading of Lexicon Pharmaceuticals
Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its stake in shares of Lexicon Pharmaceuticals by 13.4% in the third quarter. Bank of New York Mellon Corp now owns 291,660 shares of the biopharmaceutical company's stock valued at $699,000 after buying an additional 34,564 shares during the period. California State Teachers Retirement System raised its stake in shares of Lexicon Pharmaceuticals by 18.3% in the third quarter. California State Teachers Retirement System now owns 96,060 shares of the biopharmaceutical company's stock valued at $231,000 after buying an additional 14,835 shares during the period. CIBC Private Wealth Group LLC purchased a new position in shares of Lexicon Pharmaceuticals in the third quarter valued at $72,000. Alliancebernstein L.P. grew its position in shares of Lexicon Pharmaceuticals by 50.2% in the third quarter. Alliancebernstein L.P. now owns 85,011 shares of the biopharmaceutical company's stock valued at $204,000 after purchasing an additional 28,400 shares in the last quarter. Finally, State Street Corp grew its position in shares of Lexicon Pharmaceuticals by 8.3% in the third quarter. State Street Corp now owns 1,463,569 shares of the biopharmaceutical company's stock valued at $3,513,000 after purchasing an additional 111,568 shares in the last quarter.
About Lexicon Pharmaceuticals
(Get Rating)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
Further Reading
- Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
